STERTZER SIMON H
Known title: DirectorCIK: 0001031689
STERTZER SIMON H's purchase track record
How the stock did after each of STERTZER SIMON H's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 5 since March 3, 2025
Stock higher 6 months later
25%
3 months: 60%
Median 6-month return
-22.1%
3 months: +9.5%
Beat the S&P 500
25%
median -39.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/22/2026 | BCDA | $104K | +11.3% | pending | — |
| 9/19/2025 | BCDA | $498K | +9.5% | +3.5% | -2.4% |
| 6/30/2025 | BCDA | $150K | -28.2% | -36.9% | +11.3% |
| 4/23/2025 | BCDA | $200K | +29.0% | -21.5% | +24.6% |
| 3/3/2025 | BCDA | $91K | -11.7% | -22.7% | +9.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BCDA | ▲ Buy | Open Market | 39,000 | $39K | 6/23/2026 | View on chart |
| BCDA | ▲ Buy | Open Market | 70,200 | $65K | 6/22/2026 | View on chart |
| BCDA | ▲ Buy | Open Market | 398,400 | $498K | 9/19/2025 | View on chart |
| BCDA | ▲ Buy | Open Market | 72,289 | $150K | 6/30/2025 | View on chart |
| BCDA | ▲ Buy | Open Market | 104,986 | $200K | 4/23/2025 | View on chart |
| BCDA | ▲ Buy | Open Market | 1,000 | $2K | 3/5/2025 | View on chart |
| BCDA | ▲ Buy | Open Market | 15,536 | $36K | 3/4/2025 | View on chart |
| BCDA | ▲ Buy | Open Market | 22,753 | $52K | 3/3/2025 | View on chart |
| BCDA | ▲ Buy | Grant | 64,212 | $150K | 6/23/2023 | View on chart |
| BCDA | ▲ Buy | Grant | 178,571 | $300K | 12/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
BioCardia Resubmits Helix Catheter Pre-Submission to FDA
BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.
BioCardia Resubmits Helix Catheter Pre-Submission to FDA. BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.